Zobrazeno 1 - 10
of 272
pro vyhledávání: '"Diana I, Brixner"'
Autor:
Sabrina Ilham, Connor Willis, Kibum Kim, Karen C. Chung, Brenda M. Wood, Malinda S. Tan, Chia Jie Tan, Danielle T. Nguyen, Diana I. Brixner, David D. Stenehjem
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Background Diminished immune defense plays an important role in cancer development. Cancer risk in immunocompromised patients may differ. Identifying individuals with elevated cancer risk can inform strategies for routine cancer screening. T
Externí odkaz:
https://doaj.org/article/df04794d92ed426abdca967c73ed8622
Publikováno v:
Diabetes Epidemiology and Management, Vol 9, Iss , Pp 100127- (2023)
Aims: Treatment intensification (TI) may help patients with type 2 diabetes mellitus (T2DM) achieve target hemoglobin A1c (A1c) < 7.0%. This study aimed to measure the influence of TI on A1c outcome in patients who insufficiently responded to two cla
Externí odkaz:
https://doaj.org/article/067a75607fd34b80a965ae63bbf8c058
Autor:
David D. Stenehjem, Trang Au, Amy M. Sainski, Hillevi Bauer, Krystal Brown, Johnathan Lancaster, Vanessa Stevens, Diana I. Brixner
Publikováno v:
BMC Health Services Research, Vol 18, Iss 1, Pp 1-11 (2018)
Abstract Background Genetic counseling by a Genetic Counselor (GC) is a requirement prior to genetic testing for cancer susceptibility genes (GC-mandate policy) for some insurers. This study evaluated the impact of this policy from the patient perspe
Externí odkaz:
https://doaj.org/article/f3e0d21531b14d2998c6607584cdecdd
Autor:
Christina A, Brezing, Diana I, Brixner
Publikováno v:
Advances in Therapy. 39:5301-5306
Medicine is evolving to incorporate digital technologies of all kinds-technologies that may improve patient health, reduce clinician workload, lower costs, reduce health disparities, and expand access to needed treatments. Prescription digital therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff43af25936577a30d5bf2eb5ee7d14b
https://doi.org/10.1007/s12325-022-02320-0
https://doi.org/10.1007/s12325-022-02320-0
Autor:
A. Niyazov, Gary M. Oderda, Joseph Biskupiak, Ruben Gw Quek, Douglas S. Burgoyne, Linda S. Deal, Diana I. Brixner, Bhakti Arondekar
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 28:188-195
BACKGROUND: In oncology, especially with accelerated regulatory approvals and niche populations, US payers appreciate all evidence that can help support formulary decision making, including evidenc...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e053cd44d0a2f8edc1ba9f598d35c96
https://doi.org/10.18553/jmcp.2021.21223
https://doi.org/10.18553/jmcp.2021.21223
Autor:
Joseph Biskupiak, Douglas S. Burgoyne, Diana I. Brixner, Gary M. Oderda, A. Niyazov, Bhakti Arondekar
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 27:1560-1567
BACKGROUND: To support oncology formulary decisions, especially with accelerated regulatory approvals and niche populations, payers desire data beyond what regulators review. Economic models showin...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bdee814c92211383dfc53e132a831c3
https://doi.org/10.18553/jmcp.2021.27.11.1560
https://doi.org/10.18553/jmcp.2021.27.11.1560
Autor:
Phioanh L. Nghiemphu, D. Ryan Ormond, Adam L. Cohen, Diana I. Brixner, Katherine B. Peters, Nicole Willmarth, Beata Korytowsky, Prianka Singh, Connor Willis, Trang H. Au, Cornelia M. Ulrich, Alexandre H. Watanabe, Arnab Chakravarti, Jyothi Menon, Alexander Marshall, Hillevi Bauer, David D. Stenehjem, Junjie Ma, Jennie Taylor, Maija Reblin, Howard Colman
Publikováno v:
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, vol 30, iss 2
Supportive Care in Cancer
Supportive Care in Cancer
Background Glioblastoma is an incurable disease with a poor prognosis. For caregivers of people with glioblastoma, the burden of care can be high. Patients often present with different clinical characteristics, which may impact caregiver burden in di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e77a6a1b36b099f6256ea8049b2be798
https://doi.org/10.1007/s00520-021-06514-0
https://doi.org/10.1007/s00520-021-06514-0
Autor:
Boglarka Szegvari, András Inotai, Neil Hawkins, Lars Erik Kristensen, Mata Charokopou, Zoltán Kaló, Diana I. Brixner, Irina Mountian, Jonathan D. Campbell, Ivett Jakab
Publikováno v:
Inotai, A, Jakab, I, Brixner, D, Campbell, J D, Hawkins, N, Kristensen, L E, Charokopou, M, Mountian, I, Szegvari, B & Kaló, Z 2021, ' Proposal for capturing patient experience through extended value frameworks of health technologies ', Journal of Managed Care and Specialty Pharmacy, vol. 27, no. 7, pp. 936-947 . https://doi.org/10.18553/JMCP.2021.27.7.936
BACKGROUND: Inclusion of patient experience (PEx) in health technology assessment (HTA) has become increasingly important; however, no harmonized approach exists to help manufacturers or decision makers ensure PEx considerations are fair, consistent,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7dfdf647fc347b7a8b6d6733572394e
https://doi.org/10.18553/jmcp.2021.27.7.936
https://doi.org/10.18553/jmcp.2021.27.7.936
Autor:
Irina Mountian, Zoltán Kaló, Sheela Upadhyaya, Neil Bertelsen, Grammati Sarri, Andreas Freitag, Diana I. Brixner, Boglarka Szegvari
Publikováno v:
Health Policy. 125:593-601
•The value of patient experience is becoming increasingly recognized by healthcare stakeholders.•Integration of patient experience in health technology assessment is not universally adopted.•This is challenging when assessing complex health tec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32a16165afe13de2ec84d7e8e612f0c0
https://doi.org/10.1016/j.healthpol.2021.03.006
https://doi.org/10.1016/j.healthpol.2021.03.006
Autor:
Jerzy E. Tyczynski, Lia Gutierrez, Rishi Deka, Amy Sainski, Junjie Ma, Tapashi Dalvi, David D. Stenehjem, Casey R. Tak, Marisa B. Schauerhamer, Claire Telford, Joseph Biskupiak, James A. Kaye, Sudhir Unni, Diana I. Brixner, Hillevi Bauer, Xiangyang Ye
Publikováno v:
Breast Cancer Research and Treatment. 186:839-850
Germline BRCA mutations (BRCAm) strongly influence the risk of developing breast cancer. This study aimed to understand the role of BRCAm testing in affected individuals and to assess its impact on the outcome of BRCAm carriers compared to non-carrie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24d9cd4568eaf6f4d1dfff6318c4c3b1
https://doi.org/10.1007/s10549-020-06038-x
https://doi.org/10.1007/s10549-020-06038-x